ArticleScientific reports2026
Phenotypic age acceleration and genetic risk synergistically increase age-related eye disease risk in the UK Biobank.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
To evaluate the independent and synergistic effects of phenotypic age acceleration (PhenoAgeAccel) and genetic risk on age-related eye diseases (AREDs). We analyzed 395,322 participants from the UK Biobank to assess the association between PhenoAgeAccel and polygenic risk scores for age-related macular degeneration (AMD) and age-related cataract (ARC). Cox proportional hazards models evaluated independent effects and potential synergistic interactions, adjusting for demographic, socioeconomic, and lifestyle factors. PhenoAgeAccel was independently associated with increased risk of AMD (HR = 1.15, 95% CI 1.10-1.21) and ARC (HR = 1.14, 95% CI 1.12-1.17). High genetic risk conferred stronger effects for AMD (HR = 1.88, 95% CI 1.78-1.98) and ARC (HR = 1.31, 95% CI 1.27-1.35). Participants with both elevated PhenoAgeAccel and high genetic risk had markedly higher risk (AMD: HR = 2.19; ARC: HR = 1.47) compared with biologically younger, low-risk individuals. A significant multiplicative interaction was observed for AMD, indicating a synergistic effect between accelerated phenotypic aging and genetic susceptibility. PhenoAgeAccel and genetic risk each contribute to the development of AREDs, and their combination exerts a synergistic effect. Integrating aging biomarkers with genetic profiling could enhance risk stratification and inform targeted prevention strategies for ocular health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.